Brief: Abbisko Cayman Says FGFR4 Mutant Inhibitor ABSK012 Granted Orphan Drug Designation By U.S. FDA
03/04/2023 02:09
April 3 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* FGFR4 MUTANT INHIBITOR ABSK012 GRANTED ORPHAN DRUG
DESIGNATION
BY U.S. FDA FOR TREATMENT OF SOFT TISSUE SARCOMA
Source text for Eikon: ID:nHKS95tDt4
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration